Concepedia

Author

O. J. L. Loosveld

Amphia Ziekenhuis

Also Known As

Gabor I. Liposits, H. C. van Santvoort, Hjalmar C. van Santvoort, Loosveld, O, M. S. L. Liem, O J L Loosveld, O J Loosveld, O. J. L. Loosveld, O. Loosveld, O.J. Loosveld

64

Publications

3K

Citations

21

H-Index

33

Concepts

All Affiliations

Amphia ZiekenhuisRadboud University NijmegenThe Netherlands Cancer InstituteUniversity Medical Center UtrechtIsala
OJ

About

O. J. L. Loosveld is an author at Amphia Ziekenhuis specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

17

2.3K

2

Health Sciences

5

5

126

3

Hepatology

4

4

189

4

Epidemiology

1

1

30

5

Gastroenterology

1

1

562

O. J. L. Loosveld

×

26

Publications

2.5K

Citations

18

H-Index

YearCitations

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Miriam Koopman, Ninja Antonini, Joep Douma,

The Lancet

2007

626

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken,

The Lancet Oncology

2018

562

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens, Harm van Tinteren, Anne M. May,

The Lancet

2015

511

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld,

The Lancet Oncology

2023

153

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial

Paul Hamberg, Monique M.E.M. Bos, Hans J. Braun,

Clinical Breast Cancer

2011

62

Self-expanding metal stents for palliative treatment of superior vena caval syndrome

Matthijs Oudkerk, Theodore J. A. Kuijpers, Paul Schmitz,

CardioVascular and Interventional Radiology

1996

53

LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

Bas Groot Koerkamp, Quisette P. Janssen, Jacob L. van Dam,

Annals of Oncology

2023

53

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).

Miriam Koopman, Lieke H. J. Simkens, Albert J. ten Tije,

Journal of Clinical Oncology

2013

51

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial

Jacob L. van Dam, Eva M. M. Verkolf, E.N. Dekker,

BMC Cancer

2023

49

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)

Hielke J. Meulenbeld, Erik van Werkhoven, J.L. Coenen,

European Journal of Cancer

2012

35

Page 1